Readoutin 14d
Serum Institute of India Pvt. Ltd. — Cervavac as three dose regimen
Phase 3 primary completion: Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Human Papillomavirus Infection